Ca2+-independent synergistic augmentation of O2- production by FMLP and PMA in HL-60 cells

Can J Physiol Pharmacol. 1998 Oct-Nov;76(10-11):1024-32. doi: 10.1139/cjpp-76-10-11-1024.

Abstract

N-Formyl-Met-Leu-Phe (FMLP) and phorbol 12-myristate 13-acetate (PMA) caused a synergistic augmentation of superoxide anion (O2-) production in neutrophil-like HL-60 cells differentiated with dibutyryl cAMP. The present study was undertaken to investigate the mechanism of the synergistic augmentation of O2- production. FMLP increased intracellular free Ca2+ concentration ([Ca2+]i), which was slightly suppressed by PMA and completely inhibited by an intracellular Ca2+ chelating agent, O,O'-bis(2-aminophenyl)ethyleneglycol-N,N,N',N'-tetraacetic acid tetraacetoxymethyl ester (BAPTA-AM). Although FMLP-induced O2- production was inhibited by BAPTA-AM, a major part of the synergistic augmentation of O2- production by FMLP and PMA remained after BAPTA-AM treatment, suggesting that a Ca2+-independent mechanism might be involved in the augmentation. FMLP and PMA caused an activation of phospholipase D (PLD) almost additively in a Ca2+-sensitive manner. The synergistic activation of mitogen-activated protein kinase (MAPK) was evoked by combined addition of PMA and FMLP in a BAPTA-AM resistant manner. However, PD98059, a MAPK kinase inhibitor, did not affect the synergistic augmentation of O2- production, although it potently inhibited the synergistic augmentation of tyrosine phosphorylation of MAPK. Wortmannin, a phosphatidylinositol 3-kinase inhibitor, inhibited FMLP-induced O2- production, but it did not inhibit the synergistic augmentation of O2- production by PMA and FMLP. In contrast, staurosporine and GF109203X, protein kinase C inhibitors, reduced the synergistic augmentation induced by PMA and FMLP. In addition, pertussis toxin (PT) abolished the synergistic augmentation of O2- production. It is concluded that the synergistic augmentation of O2- production induced by PMA and FMLP is mediated through a PT-sensitive G protein and a protein kinase C in a Ca2+-independent manner.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arachidonic Acid / metabolism
  • Calcium / metabolism
  • Calcium / physiology*
  • Calcium-Calmodulin-Dependent Protein Kinases / drug effects
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Chelating Agents / pharmacology
  • Drug Synergism
  • Egtazic Acid / analogs & derivatives
  • Egtazic Acid / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • HL-60 Cells / drug effects
  • HL-60 Cells / metabolism
  • Humans
  • Indoles / pharmacology
  • Maleimides / pharmacology
  • N-Formylmethionine Leucyl-Phenylalanine / pharmacology*
  • Pertussis Toxin
  • Phospholipase D / drug effects
  • Phospholipase D / metabolism
  • Protein Kinase C / antagonists & inhibitors
  • Staurosporine / pharmacology
  • Superoxides / metabolism*
  • Tetradecanoylphorbol Acetate / pharmacology*
  • Time Factors
  • Virulence Factors, Bordetella / pharmacology

Substances

  • Chelating Agents
  • Enzyme Inhibitors
  • Flavonoids
  • Indoles
  • Maleimides
  • Virulence Factors, Bordetella
  • Superoxides
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Arachidonic Acid
  • Egtazic Acid
  • N-Formylmethionine Leucyl-Phenylalanine
  • Pertussis Toxin
  • Protein Kinase C
  • Calcium-Calmodulin-Dependent Protein Kinases
  • Phospholipase D
  • Staurosporine
  • bisindolylmaleimide I
  • Tetradecanoylphorbol Acetate
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Calcium